Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ALN-RSV01: Phase I data

In a double-blind, placebo-controlled Phase I trial in 109 healthy volunteers, ALN-RSV01

Read the full 121 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE